Cue Biopharma, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Cue Biopharma, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 96% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
$101Sales grew 2,106% in 3 years; of every extra $100 of sales, $101 became extra profit.
Higher than 81% of Healthcare companies in United States.
Asset Productivity Ratio
+2106% / -54%In 3 years sales changed by +2106% while total assets changed by -54%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-11.3×Operating cash was negative last year, while some debt falls due within a year.
Higher than 53% of Healthcare companies in United States.
Cash Cushion Ratio
+17%Cash, after subtracting all debt, equals 17% of its market value (net cash).
Higher than 59% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Cue Biopharma, Inc. made a loss over the last year. Cue Biopharma, Inc. owes $0.92 for every $1 it owns. Cue Biopharma, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCue Biopharma, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
59.40The share price is 59.40 times Cue Biopharma, Inc.'s book value per share, higher than 98% of Healthcare companies in United States.
Market cap
$137 MThe total market value of all of Cue Biopharma, Inc.'s shares at today's price (share price × number of shares), smaller than 62% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$2 MWhat Cue Biopharma, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.32Net worth divided by the number of shares. The share price of $18.89 is 59.4 times this, which is the P/B above.
Return on equity (ROE)
-1603.5%Cue Biopharma, Inc. lost 1603.5% of its shareholders' money over the last year, lower than 98% of Healthcare companies in United States.
Owes vs Owns
0.92×Cue Biopharma, Inc. owes $0.92 for every $1 it owns (high), higher than 84% of Healthcare companies in United States.
Dividend yield
NoneCue Biopharma, Inc. does not currently pay a dividend.
Revenue growth
+196%Revenue rose 196% in the year to Dec 2025, and grew 180% a year on average over 3 years.
Profit growth
LossCue Biopharma, Inc. made a loss in each of the last two years.
Profit margin
-96.9%Cue Biopharma, Inc. lost $97 for every $100 of revenue.
Interest cover
Not coveredCue Biopharma, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashCue Biopharma, Inc. held $23 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Cue Biopharma, Inc.: $137 M ÷ $2 M (30 Jun 2026) = 59.4.
What is Cue Biopharma, Inc.'s return on equity?
Cue Biopharma, Inc. lost 1603.5% of its shareholders' money over the last year, lower than 98% of Healthcare companies in United States.
How much does Cue Biopharma, Inc. owe compared with what it owns?
Cue Biopharma, Inc. owes $0.92 for every $1 it owns (high), higher than 84% of Healthcare companies in United States.
Does Cue Biopharma, Inc. pay a dividend?
No. Cue Biopharma, Inc. does not currently pay a dividend.
Is Cue Biopharma, Inc.'s revenue growing?
Revenue rose 196% in the year to Dec 2025, and grew 180% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.